A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer

• ClinicalTrials.gov Identifier: NCT03251378
• Recruitment Status: Active, not recruiting
• First Posted: August 16, 2017
• Last Update Posted: February 10, 2023
• Sponsor: Hutchmed
• Information provided by (Responsible Party): Hutchmed

Tracking Information

• First Submitted Date: July 19, 2017
• First Posted Date: August 16, 2017
• Last Update Posted Date: February 10, 2023
• Actual Study Start Date: November 10, 2017
• Actual Primary Completion Date: December 13, 2022 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: July 1, 2020)

• The incidence of DLT in each cohort [ Time Frame: At the end of Cycle 1 (each cycle is 28 days) ]
  The primary endpoint of the dose escalation phase is the incidence of DLT in each cohort.
• Progression free survival (PFS) at 12 weeks [ Time Frame: From first dose of study drug through 12 weeks of treatment ]
  Primary outcome expansion: progression free survival (PFS) at 12 weeks

Original Primary Outcome Measures (submitted: August 13, 2017)

Adverse Events evaluated by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.03 [ Time Frame: From first dose to within 30 days after the last dose ]

The safety and tolerability of Fruquintinib will be evaluated based on adverse events data. Other safety parameters include physical examination, vital signs, laboratory test results (i.e., hematology, chemistry panel, and urinalysis), 12-lead electrocardiogram, and ultrasonic cardiogram.

Current Secondary Outcome Measures (submitted: November 26, 2019)

• Maximum plasma concentration calculated with blood samples [ Time Frame: within 30 days after the first dose ]
  Blood samples will be taken to measure the levels of study drug
• Time to reach maximum concentration calculated with blood samples [ Time Frame: within 30 days after the first dose ]
  Blood samples will be taken to measure the levels of study drug
• Objective response rate [ Time Frame: every 4 weeks or every 8 weeks depending on cohort, through study completion, an average of 6 months ]
  the proportion of of subjects who have a Complete Response or Partial Response

Original Secondary Outcome Measures (submitted: August 13, 2017)

• To measure the time to reach maximum plasma concentration of fruquintinib in patients with advanced solid tumors. [ Time Frame: From Cycle 1, Day 1, 10 mins pre-dose 1st dose until Cycle 1, Day 22 10 mins pre-dose. ]
  The time to reach Cmax will be measured for each subject (Tmax).
• To evaluate metabolite profile (in plasma) of fruquintinib in patients with advanced solid tumors [ Time Frame: From Cycle 1, Day 1, 10 mins pre-dose 1st dose until Cycle 1, Day 22 10 mins pre-dose. ]
  The apparent clearance (CL/F) will be determined during the terminal phase according to CL/F/Ke, and the accumulation index based on AUC
• To identify the recommended study Phase II dose (RP2D). [ Time Frame: Up to 1 year. ]
  The Maximum Tolerated Dose will be identified from the Safety Run-In Phase of this Study (Arms 1 & 2)
• To evaluate anticancer activity of fruquintinib in patients with advanced solid tumors. [ Time Frame: From first dose to within 30 days after the last dose ]
  Activity will be determined according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer
• Official Title: A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients With Advanced Solid Tumors
• Brief Summary: An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability, and PK of fruquintinib in patients with advanced solid tumors, metastatic colorectal cancer and metastatic breast cancer.

Detailed Description

The study is an open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability, and PK of fruquintinib in patients with advanced solid tumors. The study will consist of two phases:

• A dose escalation phase - A 3+3 design will be used for this portion of the study.
• A dose expansion phase - Five cohorts will be evaluated in Dose Expansion. Cohort A will evaluate the MTD/RP2D in patients with advanced solid tumors. Cohort B and Cohort C will evaluate the MTD/RP2D in metastatic colorectal cancer patients. Cohort D and Cohort E will evaluate the MTD/RP2D in metastatic breast cancer patients.

Study will be conducted in up to 9 sites in the US.

• Study Type: Interventional
• Study Phase: Phase 1
• Study Design: Allocation: Non-Randomized; Intervention Model: Sequential Assignment; Masking: None (Open Label); Primary Purpose: Treatment

Condition

• Advanced Solid Tumors
• Metastatic Colon Cancer
• Metastatic Breast Cancer
• Triple Negative Breast Cancer
• HER2-negative Breast Cancer
• Hormone Receptor Positive Breast Carcinoma
• Rectal Cancer

Intervention

Drug: Fruquintinib (HMPL-013)

Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) that targets VEGFR-1, -2, and -3, with a novel chemical structure which belongs to the quinazoline class.

Other Name: HMPL-013

Study Arms

• Experimental: 3 mg Dose Escalation
  3 mg of Fruquintinib (HMPL-013), tablet taken daily, 3 weeks on, 1 week off
  Intervention: Drug: Fruquintinib (HMPL-013)
• Experimental: 5 mg Dose Escalation
  5 mg of Fruquintinib (HMPL-013), tablet taken daily, 3 weeks on, 1 week off
  Intervention: Drug: Fruquintinib (HMPL-013)
• Experimental: Fruquintinib Expansion Cohort A
  5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with advanced solid tumors.
  Intervention: Drug: Fruquintinib (HMPL-013)
• Experimental: Metastatic Colorectal Cancer Expansion Cohort B
  5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic colorectal cancer who have progressed on or had intolerable toxicity to TAS-102, regoragenib, or both.
  Intervention: Drug: Fruquintinib (HMPL-013)
• Experimental: Metastatic Colorectal Cancer Expansion Cohort C
  5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic colorectal cancer who have not been treated with TAS-102 or regorafenib.
  Intervention: Drug: Fruquintinib (HMPL-013)
• Experimental: Metastatic Breast Cancer Expansion Cohort D
  5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic Her2-negative, hormone receptor positive breast cancer.
  Intervention: Drug: Fruquintinib (HMPL-013)
• Experimental: Metastatic Breast Cancer Expansion Cohort E
  5 mg fruquintinib (HMPL-013) tablet taken daily, 3 weeks on, 1 week off in patients with metastatic triple negative (Her2-negative, ER-negative, PR-negative) breast cancer.
  Intervention: Drug: Fruquintinib (HMPL-013)

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Active, not recruiting
• Actual Enrollment (submitted: February 8, 2023): 129
• Original Estimated Enrollment (submitted: August 13, 2017): 18
• Estimated Study Completion Date: March 31, 2023
• Actual Primary Completion Date: December 13, 2022 (Final data collection date for primary outcome measure)

Eligibility Criteria

Key Inclusion Criteria:

• Fully understand the study and voluntarily sign the ICF;
• ≥18years of age;
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

Dose Escalation Phase:

• Histologically or cytologically documented, locally advanced or metastatic solid malignancy of any type (except squamous NSCLC) that has progressed on approved systemic therapy, and for whom no effective therapy or standard of care exists. This cohort is closed to enrollment.

Dose Expansion Phase:

• Cohort A: Histologically or cytologically documented, locally advanced or metastatic solid malignancy of any type (except squamous NSCLC), that has progressed on approved systemic therapy, and for whom no effective therapy or standard of care exists. This cohort is closed to enrollment.
• Cohort B: Histologically or cytologically documented mCRC in patients that have progressed on, or had intolerable toxicity with at least 1 FDA-approved third-line systemic therapy (trifluridine/tipiracil or regorafenib). Patients must also have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and an anti-EGFR therapy for patients who had RAS wild-type tumors. This cohort is currently enrolling.
• Cohort C: Histologically or cytologically documented adenocarcinoma of the colon or rectum. Patients must have progressed on, or had intolerable toxicity to, at least 2 prior regimens of standard chemotherapy, but must not have received prior TAS-102 or regorafenib. Prior therapy could have included adjuvant chemotherapy if a tumor had recurred within 6 months after the last administration of treatment. Patients must have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF biological therapy and, if RAS wild-type, an anti-EGFR therapy
• Cohort D only: Histologically- or cytologically-confirmed Her2-negative, hormone receptor positive (ER+ and/or PR+) breast cancer
• Cohort E only: Histologically- or cytologically- confirmed triple negative breast cancer

Key Exclusion Criteria:

Patients will be excluded from the study, if any of the following criteria is met:

• Severe anemia, neutropenia, thrombocytopenia
• Moderate to severe renal or hepatic impairment
• Uncontrolled hypertension
• Risk of, or active hemorrhage: history or presence of active gastric/duodenal ulcer or ulcerative colitis, active hemorrhage of an unresected gastrointestinal tumor, history of perforation of fistulas; or any other condition that could possibly result in gastrointestinal tract hemorrhage or perforation within 6 months prior to screening;
• History of a thromboembolic event (including deep vein thrombosis [DVT], pulmonary embolism, stroke and/or transient ischemic attack) within 6 months prior to screening;
• Patients with squamous NSCLC;
• Clinically significant cardiovascular disease, including but not limited to acute myocardial infarction or coronary artery bypass surgery within 6 months prior to enrollment, severe or unstable angina pectoris, New York Heart Association Class III/IV congestive heart failure, ventricular arrhythmias requiring treatment, or left ventricular ejection fraction (LVEF) <50%;
• Patients who have ever received a VEGFR inhibitor, except for patients with mCRC enrolled in the dose expansion phase;
• Systemic anti-neoplastic therapies or any investigational therapy within 4 weeks prior to the first dose of study drug, including chemotherapy, radical radiotherapy, hormonotherapy, biotherapy and immunotherapy;
• Systemic small molecule targeted therapies (eg, tyrosine kinase inhibitors) within 5 half-lives or 4 weeks (whichever is shorter) prior to the first dose of study drug;
• Palliative radiotherapy for bone metastasis/lesion within 2 weeks prior to the initiation of study drug;
• Brachytherapy (ie, implantation of radioactive seeds) within 60 days prior to the first dose of study drug;
• Known human immunodeficiency virus (HIV) infection;
• Known clinically significant history of liver disease, including cirrhosis, current alcohol abuse or active viral hepatitis. For patients with evidence of chronic hepatitis B (HBV), the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV who are currently on treatment, they are eligible if they have an undetectable HCV viral load;
• Tumor invasion of a large vascular structure, eg, pulmonary artery, superior or inferior vena cava.;
• Women who are pregnant or lactating;
• Brain metastases and/or spinal cord compression untreated with surgery and/or radiotherapy, and without clinical imaging evidence of stable disease for 14 days or longer; patients requiring steroids within 4 weeks prior to start of study treatment will be excluded;
• No other malignancy, except for non-melanoma skin cancer, during the 5 years prior to screening;
• Inability to take medication orally, dysphagia or an active gastric ulcer resulting from previous surgery (eg, gastric bypass) or a severe gastrointestinal disease, or any other condition that investigators believe may affect absorption of the investigational product;
• Other disease, metabolic disorder, physical examination anomaly, abnormal laboratory result, or any other condition that investigators suspect may prohibit use of the investigational product, affect interpretation of study results, or put the patient at undue risk of harm based on the investigator's assessment;
• Known hypersensitivity to fruquintinib or any of its excipients.
• For Cohort C only: patients who have been previously treated with TAS-102 or regorafenib

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT03251378
• Other Study ID Numbers: 2015-013-00US1
• Has Data Monitoring Committee: No

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: No

• Current Responsible Party: Hutchmed
• Original Responsible Party: Hutchison Medipharma Limited
• Current Study Sponsor: Hutchmed
• Original Study Sponsor: Hutchison Medipharma Limited
• Collaborators: Not Provided

Investigators

• Study Director: William Schelman; HUTCHMED International

• PRS Account: Hutchmed
• Verification Date: February 2023